NYSE:PRGO

Perrigo - PRGO Stock Forecast, Price & News

$37.39

+0.01 (+0.03%)

(As of 01/31/2023 10:42 AM ET)

Add

Compare

Today's Range: $37.26
▼
$37.57
50-Day Range: $31.12
▼
$37.38
52-Week Range: $30.78
▼
$43.90

Volume: 55,999 shs
Average Volume: 908,105 shs
Market Capitalization: $5.03 billion

P/E Ratio: N/A
Dividend Yield: 2.80%
Price Target: $47.33

Institutional Ownership

Perrigo MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 26.6% Upside
$47.33 Price Target
Short Interest: Healthy
4.21% of Shares Sold Short
Dividend Strength: Strong
Based on Four Factors
Sustainability: -1.93
Upright™ Environmental Score
News Sentiment: 0.30
Based on 4 Articles This Week
Insider Trading: Selling Shares
$74,947 Sold Last Quarter
Proj. Earnings Growth: 37.62%
From $2.02 to $2.78 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.91 out of 5 stars

Medical Sector

28th out of 1,055 stocks

Pharmaceutical Preparations Industry

12th out of 518 stocks

3.5

Analyst's Opinion

Consensus Rating
Perrigo has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $47.33, Perrigo has a forecasted upside of 26.6% from its current price of $37.38.
Amount of Analyst Coverage
Perrigo has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
4.21% of the outstanding shares of Perrigo have been sold short.
Short Interest Ratio / Days to Cover
Perrigo has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Perrigo has recently increased by 17.15%, indicating that investor sentiment is decreasing significantly.

3.3

Dividend Strength

Dividend Yield
Perrigo pays a meaningful dividend of 2.80%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Perrigo has been increasing its dividend for 20 years.
Dividend Sustainability
Based on earnings estimates, Perrigo will have a dividend payout ratio of 37.41% next year. This indicates that Perrigo will be able to sustain or increase its dividend.

3.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Perrigo has received a 41.09% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Anti-diarrheal and intestinal anti-inflammatory medication (A07)", "Dental floss", "Antifungal medication (D01) ", "Cough and cold medication (R05)", and "Toothbrushes" products. See details.
Environmental Sustainability
The Environmental Impact score for Perrigo is -1.93.

1.3

News and Social Media Coverage

News Sentiment
Perrigo has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Perrigo this week, compared to 4 articles on an average week.
MarketBeat Follows
Only 2 people have added Perrigo to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Perrigo insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $74,947.00 in company stock.
Percentage Held by Insiders
Only 0.80% of the stock of Perrigo is held by insiders.
Percentage Held by Institutions
94.09% of the stock of Perrigo is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

2.5

Earnings and Valuation

Earnings Growth
Earnings for Perrigo are expected to grow by 37.62% in the coming year, from $2.02 to $2.78 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Perrigo is -59.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Perrigo is -59.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Perrigo has a P/B Ratio of 0.97. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Perrigo (NYSE:PRGO) Stock

Perrigo Co. Plc engages in the provision of self-care products and over-the-counter (OTC) health and wellness solutions. It enhances individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. It operates through the following segments: Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment offers OTC solutions, infant formula, oral care, and contract manufacturing in the U.S, Mexico, and Canada. The CSCI segment includes the self-care business branded in Europe, Australia, the United Kingdom, and parts of Europe and Asia. The company was founded by Luther Perrigo in 1887 and is headquartered in Dublin, Ireland.

Receive PRGO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Perrigo and its competitors with MarketBeat's FREE daily newsletter.

PRGO Stock News Headlines

December 26, 2022 | thestreet.com

Perrigo (PRGO) Stock Plunging on Failed Mylan Deal

December 19, 2022 | finance.yahoo.com

Perrigo to Host Virtual Investor Day on February 28, 2023

January 31, 2023 | PressReach (Ad)

Top Lithium Stock

Today's stock market report features a battery metal lithium stock with great potential.

December 16, 2022 | finance.yahoo.com

SWEDEN’S SKINCARE SENSATION ACO EXTENDS PRESENCE INTO US TIMED TO THE HOLIDAY SEASON

December 16, 2022 | investing.com

Perrigo Co. PT Lowered to $45 at JPMorgan

December 1, 2022 | finance.yahoo.com

Reckitt Benckiser expects baby formula shortage to continue into spring 2023

November 10, 2022 | finance.yahoo.com

‘Long-term investors should turn back toward stocks’: J.P. Morgan says inflation has peaked and suggests 2 stocks to buy